Working… Menu
Trial record 36 of 82 for:    GRAZOPREVIR ANHYDROUS AND ELBASVIR

Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02204475
Recruitment Status : Withdrawn
First Posted : July 30, 2014
Last Update Posted : October 14, 2015
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
This is a randomized, multi-site, open-label trial of a fixed-dose combination of Grazoprevir (MK-5172) and Elbasvir (MK-8742) versus Boceprevir (BOC) / Pegylated Interferon (P) and Ribavirin (R) in treatment-naive and prior treatment failure genotype (GT) 1 hepatitis C virus (HCV)-infected participants. The primary hypothesis is that the proportion of treatment-naive (TN) and prior treatment failure (PTF) participants treated with grazoprevir + elbasvir achieving sustained virologic response (undetectable HCV ribonucleic acid [RNA]) 12 weeks after the end of study therapy (SVR12) will be greater than the proportion of BOC/PR-treated participants achieving SVR12.

Condition or disease Intervention/treatment Phase
Hepatitis C Drug: Grazoprevir/Elbasvir Drug: Boceprevir Drug: PegIntron Drug: Ribavarin Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 Versus Boceprevir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR Prior Treatment Failure Subjects With Chronic HCV GT1 Infection
Study Start Date : November 2014
Estimated Primary Completion Date : June 2016
Estimated Study Completion Date : September 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: BOC/PR
All participants begin treatment with a 4-week lead-in of PR followed by 24 weeks of BOC/PR. At Treatment Week (TW) 28 TN participants who have undetectable HCV RNA at TW 8 will complete BOC/PR therapy. At TW 28 TN participants who have detectable HCV RNA at TW 8, as well as prior relapsers and prior partial responders, will continue on BOC/PR for an additional 8 weeks and then continue on PR for an additional 12 weeks. At TW 28 all cirrhotics and previous null responders will continue on BOC/PR for an additional 20 weeks.
Drug: Boceprevir
Participants take Boceprevir (BOC) 800 mg three times daily (TID) PO.

Drug: PegIntron
Participants take 1.5 mcg/kg PegIntron (P) once weekly (QW) via subcutaneous injection.
Other Name: Pegylated Interferon

Drug: Ribavarin
Participants take Ribavarin (R) 800-1400 mg (depending on body weight) twice daily (BID) PO.

Experimental: Grazoprevir/Elbasvir
Participants will undergo treatment with grazoprevir 100 mg + elbasvir 50 mg for 12 weeks.
Drug: Grazoprevir/Elbasvir
Participants take a fixed-dose combination of grazoprevir 100 mg and elbasvir 50 mg once daily (QD) by mouth (PO).

Primary Outcome Measures :
  1. Proportion of participants achieving SVR12 [ Time Frame: Up to Week 60 ]

Secondary Outcome Measures :
  1. Proportion of TN participants achieving SVR12 [ Time Frame: Up to Week 60 ]
  2. Number of participants experiencing an adverse event (AE) [ Time Frame: Up to Week 72 ]
  3. Number of participants withdrawing from study treatment due to AEs [ Time Frame: Up to Week 72 ]
  4. Proportion of PTF participants achieving SVR12 [ Time Frame: Up to Week 60 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Has HCV RNA ≥ 10,000 IU/mL at the time of screening
  • Has documented chronic HCV GT 1 with no evidence of non-typeable or mixed GT infection
  • Is cirrhotic or non-cirrhotic
  • Has HCV treatment status that is treatment naïve, PR null responder; PR partial responder; or prior PR relapser
  • If human immunodeficiency virus (HIV) co-infected (HIV-1) must be naïve to treatment with any antiretroviral therapy (ART) and have no plans to initiate ART treatment while participating in this trial, or be on HIV ART for at least 8 weeks prior to trial entry (no changes in HIV regimen are allowed within 4 weeks of registration); must also have at least one viable antiretroviral therapy alternative beyond their current regimens in the event of HIV virologic failure and the development of antiretroviral drug resistance
  • Use an acceptable method of contraception or not be of childbearing potential

Exclusion Criteria:

  • Has evidence of decompensated liver disease manifested by the presence of or history of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other signs or symptoms of advanced liver disease
  • Is co-infected with hepatitis B virus (e.g., hepatitis B surface antigen [HBsAg] positive)
  • Has a history of malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or carcinoma in situ; or is under evaluation for other active or suspected malignancy
  • Has cirrhosis and liver imaging within 6 months of Day 1 showing evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC
  • Has pre-existing psychiatric condition(s)
  • Has clinically-relevant drug or alcohol abuse within 12 months of screening
  • Is a female and is pregnant or breast-feeding, or expecting to become pregnant or donate eggs from Day 1 throughout treatment and until at least 6 months after the last dose of study medication, or longer if dictated by local regulations; or is a male subject and is planning to impregnate or provide sperm donation
  • Has any preexisting condition or prestudy laboratory abnormality, electrocardiogram (ECG) abnormality or history of any illness, which, in the opinion of the investigator, might confound the results of the trial or pose additional risk in administering the study drug(s) to the subject
  • Has a life-threatening severe AE (SAE) during the screening period
  • Has evidence of history of chronic hepatitis not caused by HCV, including but not limited to nonalcoholic steatohepatitis (NASH), drug-induced hepatitis, and autoimmune hepatitis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02204475

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Layout table for investigator information
Study Director: Medical Director Merck Sharp & Dohme Corp.

Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT02204475     History of Changes
Other Study ID Numbers: 5172-066
2014-001841-25 ( EudraCT Number )
First Posted: July 30, 2014    Key Record Dates
Last Update Posted: October 14, 2015
Last Verified: October 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Peginterferon alfa-2b
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents